Literature DB >> 20609773

Marrow stromal cells for cell-based therapy: the role of antiinflammatory cytokines in cellular cardiomyoplasty.

Guangyong Chen1, Madhur Nayan, Minh Duong, Juan-Francisco Asenjo, Yin Ge, Ray C-J Chiu, Dominique Shum-Tim.   

Abstract

BACKGROUND: The mechanism by which marrow stromal cells (MSCs) improve cardiac function after myocardial infarction (MI) is still unclear. Because MI patients with lower circulating proinflammatory/antiinflammatory cytokine ratios have been reported to have a better prognosis and in vitro studies showed that MSCs express antiinflammatory cytokines, we hypothesized that changes in cytokine ratios in the infarct microenvironment after MSC therapy may play a role in improving early cardiac function after MI.
METHODS: Sixty-three rats that survived left coronary artery ligations were injected with culture media (group M) or MSCs (group C). Cardiac functional changes were assessed with echocardiography. Cytokine gene expressions of interleukin (IL)-1beta, IL-6, IL-8, (proinflammatory) and IL-10 (antiinflammatory) were quantified by real-time polymerase chain reaction. Extracellular matrix deposition, injury score, and the matrix metallopeptidase 2/tissue inhibitor of metallopeptidase 1 ratio were also analyzed.
RESULTS: The ratio of proinflammatory/antiinflammatory cytokine gene expression was decreased in group C at various times, particularly in the early postoperative period. In group C, the matrix metallopeptidase 2/tissue inhibitor of metallopeptidase 1 gene expression ratio was significantly lower than group M at the early phase (12 hours), which in group C was translated into significantly lower extracellular matrix deposition at 24 hours, 1, and 2 weeks. Functional recovery was also significantly better in cell therapy group C.
CONCLUSIONS: Our data demonstrate that MSC therapy decreases the proinflammatory/antiinflammatory cytokine ratio in the microenvironment early after MI. This is associated with subsequent less scar formation and improved cardiac function. Copyright 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20609773     DOI: 10.1016/j.athoracsur.2010.02.074

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  14 in total

1.  Tracking fusion of human mesenchymal stem cells after transplantation to the heart.

Authors:  Brian T Freeman; Nicholas A Kouris; Brenda M Ogle
Journal:  Stem Cells Transl Med       Date:  2015-04-06       Impact factor: 6.940

2.  Perceived relationship support moderates the association of contextual stress with inflammation among African Americans.

Authors:  Steven R H Beach; Man Kit Lei; Ronald L Simons; Ashley B Barr; Leslie G Simons; Carolyn E Cutrona; Robert A Philibert
Journal:  J Fam Psychol       Date:  2019-02-11

3.  The birth of 'regenerative pharmacology': a clinical perspective.

Authors:  T R Choudhury; A Mathur
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

Review 4.  Immunomodulatory plasticity of mesenchymal stem cells: a potential key to successful solid organ transplantation.

Authors:  Urvashi Kaundal; Upma Bagai; Aruna Rakha
Journal:  J Transl Med       Date:  2018-02-15       Impact factor: 5.531

5.  Exploitation of herpesvirus immune evasion strategies to modify the immunogenicity of human mesenchymal stem cell transplants.

Authors:  Anabel S de la Garza-Rodea; Marieke C Verweij; Hester Boersma; Ietje van der Velde-van Dijke; Antoine A F de Vries; Rob C Hoeben; Dirk W van Bekkum; Emmanuel J H J Wiertz; Shoshan Knaän-Shanzer
Journal:  PLoS One       Date:  2011-01-06       Impact factor: 3.240

6.  Superior therapeutic potential of young bone marrow mesenchymal stem cells by direct intramyocardial delivery in aged recipients with acute myocardial infarction: in vitro and in vivo investigation.

Authors:  Madhur Nayan; Arghya Paul; Guangyong Chen; Ray C J Chiu; Satya Prakash; Dominique Shum-Tim
Journal:  J Tissue Eng       Date:  2011-07-24       Impact factor: 7.813

7.  Mesenchymal stromal cells for cardiovascular disease.

Authors:  Ian B Copland
Journal:  J Cardiovasc Dis Res       Date:  2011-01

8.  Bone marrow stem cell derived paracrine factors for regenerative medicine: current perspectives and therapeutic potential.

Authors:  Tom J Burdon; Arghya Paul; Nicolas Noiseux; Satya Prakash; Dominique Shum-Tim
Journal:  Bone Marrow Res       Date:  2010-12-06

9.  Intramyocardial sustained delivery of placental growth factor using nanoparticles as a vehicle for delivery in the rat infarct model.

Authors:  Ziyad Mohammed Binsalamah; Arghya Paul; Afshan Afsar Khan; Satya Prakash; Dominique Shum-Tim
Journal:  Int J Nanomedicine       Date:  2011-10-31

10.  Directed Fusion of Mesenchymal Stem Cells with Cardiomyocytes via VSV-G Facilitates Stem Cell Programming.

Authors:  Nicholas A Kouris; Jeremy A Schaefer; Masato Hatta; Brian T Freeman; Timothy J Kamp; Yoshihiro Kawaoka; Brenda M Ogle
Journal:  Stem Cells Int       Date:  2012-05-30       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.